Insulin Isophane 70% + Human insulin 30%

Insulin Isophane 70% + Human Insulin 30% is a premixed human insulin formulation containing 70% insulin isophane, also known as NPH insulin, and 30% regular human insulin. It combines intermediate-acting insulin with short-acting insulin in a fixed ratio to help manage blood glucose levels in people with diabetes mellitus. Regular human insulin begins lowering blood glucose after injection and helps control the rise associated with meals, while insulin isophane provides a more prolonged effect between meals and over part of the day or night. Both components act by binding to insulin receptors, promoting glucose uptake in muscle and fat and reducing glucose production by the liver. The formulation is generally administered by subcutaneous injection and is commonly scheduled around meals according to the specific product instructions. Because the two insulin components are combined in a fixed proportion, the dose cannot be adjusted independently for the mealtime and intermediate-acting components. This can simplify treatment for some patients but requires consistent meal timing, appropriate food intake, and regular glucose monitoring. The exact dose and schedule must be individualised according to diabetes type, glucose readings, daily routine, other medicines, and clinical response.

Premixed human insulin formulations were developed to combine mealtime and intermediate-acting insulin in a single preparation, supporting patients who benefit from a fixed insulin ratio. Insulin isophane contains human insulin complexed with protamine to delay absorption, while regular human insulin provides a shorter-acting glucose-lowering effect. These formulations have been used in diabetes care for decades. In the United States, the FDA initially approved Humulin 70/30 in 1989 and Novolin 70/30 in 1991 for improving glycaemic control, with the precise approved populations and product instructions depending on the formulation. In India, 70% isophane human insulin and 30% human insulin formulations have also been documented in regulatory and pharmaceutical records. Premixed insulin products have been evaluated in clinical studies assessing blood glucose control and safety compared with other insulin regimens. Approval status, concentration, age eligibility, and administration instructions can differ by product and country, so the applicable local prescribing information should be followed.

Insulin Isophane 70% + Human Insulin 30% is used to improve blood glucose control in people with diabetes mellitus when a combination of intermediate-acting and short-acting insulin is appropriate. It may be prescribed for type 2 diabetes when other treatments do not provide adequate glucose control or when insulin therapy is clinically indicated. Depending on the specific product's approved indication and the patient's needs, premixed human insulin may also be used in selected patients with type 1 diabetes as part of an individualised insulin regimen. The formulation provides basal and mealtime insulin activity in a fixed ratio, so it is most suitable for people whose meal patterns and insulin requirements can be managed with that combination. It may be used as the principal insulin regimen or alongside other glucose-lowering treatments when clinically appropriate. It is not intended to treat diabetic ketoacidosis.

Insulin Isophane 70% + Human Insulin 30% is administered by subcutaneous injection, commonly into the abdomen, thigh, upper arm, or buttocks, according to the product instructions. Many conventional premixed human insulin products are administered approximately 30 minutes before a meal, but the precise timing must follow the specific formulation's prescribing information. Dosing is individualised according to diabetes type, previous insulin treatment, blood glucose readings, meal patterns, physical activity, and treatment goals. Some patients require one or two daily injections, while others may need a different schedule determined by their healthcare professional. The two components cannot be adjusted separately because they are supplied in a fixed ratio. The suspension should be resuspended as directed before use, and the correct appearance and dose should be checked. It must not be administered intravenously or used in an insulin pump unless the specific product information explicitly permits it. Regular glucose monitoring and supervised dose adjustments are essential.

The most important common side effect of Insulin Isophane 70% + Human Insulin 30% is hypoglycaemia, or low blood glucose. Symptoms can include sweating, trembling, hunger, dizziness, headache, confusion, and a rapid heartbeat. Other possible effects include weight gain, injection-site redness, itching or discomfort, and changes in the fatty tissue beneath the skin, such as thickening or indentations when injections are repeatedly given in the same area. Temporary swelling may also occur. The risk of hypoglycaemia can increase when meals are delayed or missed, physical activity increases unexpectedly, or the insulin dose is greater than required. Side effects vary between individuals. Patients should learn to recognise low blood glucose, understand how to manage it, and seek medical advice if symptoms recur or injection-site reactions persist.

Severe hypoglycaemia can cause seizures, loss of consciousness, injury, or other life-threatening complications and requires urgent treatment. Serious allergic reactions, including anaphylaxis, are possible but uncommon. Insulin can also lower blood potassium levels, which may be dangerous in susceptible patients. Incorrect dosing, changes in meal timing, or an interruption in insulin treatment can lead to significant glucose disturbances; inadequate insulin in people with type 1 diabetes can result in diabetic ketoacidosis. The formulation should not be used during an episode of hypoglycaemia or by a person with a known serious hypersensitivity to the relevant product or its ingredients. Because the preparation contains a fixed ratio of short-acting and intermediate-acting insulin, it may be unsuitable when highly flexible adjustment of mealtime and basal insulin is needed. Patients should not change the dose or stop treatment without medical guidance. Insulin pens, cartridges, and syringes must never be shared between patients.

Insulin requirements may change in people with kidney or liver impairment, older adults, during pregnancy, or when diet, physical activity, body weight, or general health changes. Medicines such as other glucose-lowering agents may increase the risk of hypoglycaemia, while corticosteroids, some diuretics, thyroid hormones, and certain other medicines may raise blood glucose or alter insulin requirements. Beta-blockers can mask some warning signs of hypoglycaemia, and alcohol may increase or prolong the risk of low blood glucose. Patients should inform their healthcare professional about all prescription medicines, non-prescription products, and supplements they use. Regular meals and consistent carbohydrate intake can be particularly important with premixed insulin because its components cannot be adjusted independently. Injection sites should be rotated, and the suspension must be stored according to the specific product instructions, protected from excessive heat and freezing. Patients should not change brands, concentrations, or delivery devices without professional advice.

Before prescribing this premixed insulin, assess the patient's diabetes type, glucose profile, meal routine, previous insulin regimen, risk of hypoglycaemia, kidney and liver function, and ability to use the delivery device safely. Confirm the exact insulin ratio, concentration, and prescribed dose, as different insulin formulations are not automatically interchangeable. Explain the importance of meal timing, consistent food intake, glucose monitoring, correct resuspension of the suspension, and rotation of injection sites. Ensure patients can recognise and manage hypoglycaemia and know when urgent medical assistance is required. Review glucose records after starting treatment or changing the dose, and reassess the regimen when eating patterns, activity levels, illness, pregnancy, or interacting medicines change. Because the formulation has a fixed ratio, consider whether it provides sufficient flexibility for the patient's daily routine and glucose pattern. Pharmacists should reinforce product-specific storage instructions and check that patients understand the correct use of their prescribed pen, cartridge, or vial.